Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Mer­ck is ac­quir­ing a start­up spun out of Yale called Mod­i­fi Bio, which has de­vel­oped a suite of mol­e­cules against chemother­a­py-re­sis­tant glioblas­toma, a dev­as­tat­ing and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER